Skip to main content

Table 3 The association between magnesium-zinc-calcium-vitamin D co-supplementation and pregnancy outcomes

From: The effects of magnesium-zinc-calcium-vitamin D co-supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes

 

Placebo group (n = 30)

Magnesium-zinc-calcium-vitamin D group (n = 30)

P1

Cesarean section (%)

9 (30.0)

4 (13.3)

0.11

Preterm delivery (%)

1 (3.3)

0 (0.0)

0.31

Need to insulin therapy after intervention (%)

2 (6.7)

1 (3.3)

0.55

Pre-eclampsia (%)

3 (10.0)

2 (6.7)

0.64

Polyhydramnios (%)

2 (6.7)

1 (3.3)

0.55

Macrosomia > 4000 g (%)

5 (16.7)

1 (3.3)

0.08

Gestational age (weeks)

39.2 ± 1.1

39.1 ± 1.2

0.90

Newborns’ weight (g)

3346.3 ± 411.1

3089.8 ± 519.9

0.05

Newborns’ length (cm)

50.0 ± 1.4

49.2 ± 3.6

0.28

Newborns’ head circumference (cm)

35.2 ± 1.7

34.4 ± 3.0

0.20

1- min Apgar score

8.8 ± 0.4

8.9 ± 0.3

0.45

5- min Apgar score

9.8 ± 0.4

9.9 ± 0.3

0.45

Newborns’ hyperbilirubinemia (%)

12 (40.0)

8 (26.7)

0.27

Newborns’ hospitalization (%)

12 (40.0)

8 (26.7)

0.27

  1. Values are means± SDs for continuous measures and are number (%) for dichotomous variables
  2. 1Obtained from independent t-test
  3. Obtained from Pearson Chi-square test